Halberd Corporation Continues Seeking Government Contracts with Scientists at Mississippi State University
MWN-AI** Summary
Halberd Corporation (OTC: HALB) is actively pursuing government contracts in collaboration with scientists from Mississippi State University to fund advanced animal research aimed at developing effective treatments for Traumatic Brain Injury (TBI). This endeavor is particularly focused on creating a post-head-trauma treatment that could be beneficial for military personnel and others affected by head injuries due to sports, accidents, or other incidents.
The treatment, a simple multi-part nasal spray, is designed for immediate administration following head trauma and aims to mitigate the adverse effects associated with TBI. Halberd's research indicates that this nasal spray has the potential to reduce biochemical changes and behavioral deficits linked to TBI, building on previous Phase-1 studies that showed promising results in animals.
The sought government contract will finance Phase-2 animal research, which will utilize advanced techniques, including Artificial Intelligence capabilities from Halberd's acquisition of NeuroSense AI. The potential benefits for military applications, such as an expedited return-to-duty following head trauma, further underscore the significance of this research.
Although there are currently no plans for Phase-3 trials, future studies may involve larger animal models or preliminary human testing. Alongside pursuing government funding, Halberd is exploring private investment and potential corporate restructuring to support its initiatives.
Halberd Corporation emphasizes the importance of innovation in healthcare, focusing on developing advanced treatments and diagnostic technologies. The company's commitment to improving health outcomes is reinforced by strategic partnerships with prominent research institutions, ensuring robust scientific endorsement of its solutions. Updates about ongoing developments can be found on Halberd's website and through their communication channels.
MWN-AI** Analysis
Halberd Corporation (OTC: HALB) is positioned at an intriguing intersection of healthcare innovation and government collaboration, particularly with its ongoing partnership with Mississippi State University. Investors should closely monitor Halberd's strategic move to secure government contracts aimed at advancing treatments for Traumatic Brain Injury (TBI), a pressing issue affecting numerous military personnel and civilians alike.
The development of a nasal spray treatment that can mitigate TBI symptoms is compelling. The U.S. military's historical struggles with TBI and related mental health issues present a sizeable potential market for this product, particularly given the emphasis on early intervention and return-to-duty timelines for service members. The combination of proven Phase-1 results and the forthcoming Phase-2 research utilizing AI capabilities from Halberd's acquisition of NeuroSense AI enhances the credibility and potential effectiveness of their treatment protocol.
Investors should note that while Halberd is actively pursuing funding from federal contracts, they are also exploring private investments and corporate restructuring. This dual approach may indicate a proactive stance to bolster their financial standing while pursuing ambitious research goals. Regular updates promised by the company suggest that transparency will be prioritized, which is beneficial for potential investors seeking to gauge progress and viability.
However, the inherent risks in biotechnology ventures, including regulatory hurdles and market competition, should not be overlooked. As Halberd navigates the critical Phase-2 research and targets broader markets, enthusiasm among investors can fluctuate significantly based on interim results and partnerships.
In summary, Halberd Corporation occupies a space full of promise within the healthcare landscape. Their ongoing initiatives could yield valuable breakthroughs, but prudent investors should maintain a balanced perspective on the associated risks versus potential returns as developments unfold.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
JACKSON CENTER, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB), through its collaboration with scientists at Mississippi State University, continues work on a planned fourth quarter submission to the United States government seeking contractual funding for advanced animal research for the development of an effective post-head-trauma treatment for Traumatic Brain Injury (TBI).
The United States military, for example, has historically experienced rates of suicide among both active duty and veteran groups reaching as high as one per hour. Head trauma associated with contact sports, falls, and automobile accidents has been associated with an increased risk of developing Alzheimer's Disease, Parkinson's Disease, and Epilepsy. The Halberd treatment is a simple multi-part nasal spray that can be first implemented immediately following head trauma and then continued during the initial stages of recovery. This early intervention allows for the effective mitigation of the negative effects associated with TBI.
The government contract that is sought will be used to finance pre-planned, advanced Phase-2 animal research that is designed to determine the efficacy of the nasal spray to reduce the level of biochemical changes and behavioral deficits that can be induced by different levels of TBI that originate from different sources (blasts and impacts). This work is based on previous simpler Phase-1 testing that demonstrated a reduction in the level of markers of TBI-induced damage in the brains of animals that received the nasal spray as compared to those that did not.
The Phase-2 tests will employ the Artificial Intelligence capabilities afforded by Halberd's recent acquisition of NeuroSense AI. Phase-3 tests have not yet been planned, but could involve larger animals and/or preliminary human trials.
A potential advantage of the Halberd nasal spray to the military is an expedited return-to-duty following head trauma or elevated anxiety conditions. This could be a very important aspect of the proprietary Halberd nasal spray to the military.
Halberd is also pursuing private investment and possible corporate restructuring, and will provide pertinent timely updates in future press releases.
To get the latest on Halberd’s exciting developments, subscribe by submitting this form .
( https://halberdcorporation.com/contact-us/ ).
For more information, please contact:
William A. Hartman
[email protected]
[email protected]
www.halberdcorporation.com
X: @HalberdC
About Mississippi State University College of Veterinary Medicine (CVM)
Established in 1974, the Mississippi State University College of Veterinary Medicine (MSU CVM) comprises six locations, catering to all 82 counties in Mississippi and the broader Southeastern United States. The primary campus, situated in Starkville, encompasses the Wise Center, home to the main teaching hospital known as the Animal Health Center. The faculty and staff of the MSU CVM Department of Comparative Biomedical Sciences cover fundamental scientific disciplines essential for veterinary education. MSU CVM is dedicated to an ethical approach in the treatment of animals, demonstrating a sincere passion and commitment.
About NeuroSense AI
NeuroSense AI is a behavioral intelligence platform in development by Halberd Corporation, designed to transform preclinical TBI research through multi-modal behavioral analysis and advanced AI interpretation. The platform combines ultrasonic vocalization analysis, micro-movement tracking, and social behavior monitoring with Claude AI-powered pattern recognition to provide objective, continuous assessment of neurological function and recovery. For more information, visit NeuroSenseAI.ai
About Halberd Corporation.
Halberd Corporation (OTC: HALB ) is a technology holding company focused on developing breakthrough solutions for healthcare and medical applications. The Company's portfolio includes innovative approaches to disease treatment, diagnostic technologies, and AI-powered healthcare platforms. Halberd is committed to improving human health outcomes through advanced technology development and strategic partnerships with leading research institutions.
Safe Harbor Notice
This press release contains forward-looking statements regarding Halberd Corporation's business prospects and its NeuroSense AI platform. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company’ cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.
FAQ**
How does Halberd Corp HALB plan to utilize the funding from the United States government to advance Phase-2 animal research for their TBI treatment, and what specific outcomes do they hope to achieve?
What unique advantages does the Halberd nasal spray offer to the military, and how does Halberd Corp HALB envision its impact on the return-to-duty rates for service members after head trauma?
Can Halberd Corp HALB provide more details on the collaboration with Mississippi State University and how this partnership enhances the credibility and effectiveness of their TBI treatment research?
In light of Halberd Corp HALB's recent acquisition of NeuroSense AI, what role will artificial intelligence play in evaluating the effectiveness of the nasal spray treatment during the Phase-2 animal research trials?
**MWN-AI FAQ is based on asking OpenAI questions about Halberd Corp (OTC: HALB).
NASDAQ: HALB
HALB Trading
-6.67% G/L:
$0.0014 Last:
30,400 Volume:
$0.0015 Open:
